1. Home
  2. WOLF vs EVO Comparison

WOLF vs EVO Comparison

Compare WOLF & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolfspeed Inc.

WOLF

Wolfspeed Inc.

HOLD

Current Price

$58.23

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.06

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WOLF
EVO
Founded
1987
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.1B
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
WOLF
EVO
Price
$58.23
$3.06
Analyst Decision
Sell
Strong Buy
Analyst Count
4
1
Target Price
$14.33
$7.00
AVG Volume (30 Days)
10.0M
47.1K
Earning Date
05-05-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,385,982,000.00
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$7.43
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
19.00
N/A
52 Week Low
$0.39
$2.31
52 Week High
$80.82
$4.42

Technical Indicators

Market Signals
Indicator
WOLF
EVO
Relative Strength Index (RSI) 57.70 56.03
Support Level $15.86 $2.88
Resistance Level $73.74 $3.75
Average True Range (ATR) 10.79 0.07
MACD -0.64 0.01
Stochastic Oscillator 40.64 89.58

Price Performance

Historical Comparison
WOLF
EVO

About WOLF Wolfspeed Inc.

Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: